{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:14:37Z","timestamp":1787728477595,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.oret.2025.02.002","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T19:13:11Z","timestamp":1738955591000},"page":"756-766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Initial Functional and Anatomical Outcomes of High-dose Aflibercept 8 mg in Exudative Neovascular Age-related Macular Degeneration"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6754-7199","authenticated-orcid":false,"given":"Suraj","family":"Bala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3169-1097","authenticated-orcid":false,"given":"Gabriel C.S.","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-9504","authenticated-orcid":false,"given":"Nitesh","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5126-045X","authenticated-orcid":false,"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananth","family":"Sastry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0782-2694","authenticated-orcid":false,"given":"Amy S.","family":"Babiuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7007-6938","authenticated-orcid":false,"given":"Jonathan","family":"Sears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0191-8035","authenticated-orcid":false,"given":"Alex","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Rachitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6763-7768","authenticated-orcid":false,"given":"Justis P.","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-3283","authenticated-orcid":false,"given":"Andrew P.","family":"Schachat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-5470","authenticated-orcid":false,"given":"Phoebe","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5769-0717","authenticated-orcid":false,"given":"Sumit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7496-5118","authenticated-orcid":false,"given":"Danny A.","family":"Mammo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.02.002_bib1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.oret.2025.02.002_bib2","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2025.02.002_bib3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2147\/OPTH.S231913","article-title":"Neovascular age-related macular degeneration (nAMD): a review of emerging treatment options","volume":"16","author":"Tan","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.02.002_bib4","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.02.002_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of Ophthalmology","volume":"126","author":"Bakri","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.02.002_bib6","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/eye.2017.143","article-title":"Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set","volume":"31","author":"Lotery","year":"2017","journal-title":"Eye"},{"key":"10.1016\/j.oret.2025.02.002_bib7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12325-019-01147-6","article-title":"Real-world effectiveness and real-world cost-effectiveness of intravitreal aflibercept and intravitreal ranibizumab in neovascular age-related macular degeneration: systematic review and meta-analysis of real-world studies","volume":"37","author":"Carrasco","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.oret.2025.02.002_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","article-title":"Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy","volume":"8","author":"Szigiato","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.02.002_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.oret.2019.01.018","article-title":"Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a \u201ctreat-and-extend\u201d regimen","volume":"3","author":"Traine","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.02.002_bib10","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/IAE.0000000000002670","article-title":"Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from LUMINOUS, a global real-world study","volume":"40","author":"Holz","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.02.002_bib11","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/eye.2017.81","article-title":"Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option","volume":"31","author":"Ashraf","year":"2017","journal-title":"Eye"},{"key":"10.1016\/j.oret.2025.02.002_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OPTH.S151611","article-title":"Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients","volume":"12","author":"Ehlken","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.02.002_bib13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jfo.2014.11.015","article-title":"Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting","volume":"38","author":"Boulanger-Scemama","year":"2015","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.oret.2025.02.002_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189035","article-title":"The impact of different anti-vascular endothelial growth factor treatment regimens on reducing burden for caregivers and patients with wet age-related macular degeneration in a single-center real-world Japanese setting","volume":"12","author":"Hanemoto","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2025.02.002_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.02.002_bib16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2025.02.002_bib17","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2025.02.002_bib19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","article-title":"Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial","volume":"141","author":"Wykoff","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.02.002_bib21","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1167\/iovs.05-0981","article-title":"Visual acuities \u201chand motion\u201d and \u201ccounting fingers\u201d can be quantified with the Freiburg Visual Acuity Test","volume":"47","author":"Schulze-Bonsel","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2025.02.002_bib22","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing Snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.02.002_bib23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41433-023-02637-2","article-title":"Exploring the role of retinal fluid as a biomarker for the management of diabetic macular oedema","volume":"38","author":"Khoramnia","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.oret.2025.02.002_bib24","doi-asserted-by":"crossref","first-page":"14166","DOI":"10.1038\/s41598-022-18158-z","article-title":"A real-world study assessing the impact of retinal fluid on visual acuity outcomes in patients with neovascular age-related macular degeneration in Korea","volume":"12","author":"Kim","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2025.02.002_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bjo-2022-322297","article-title":"Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration national database","volume":"108","author":"Martin-Pinardel","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.02.002_bib26","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jamaophthalmol.2022.1357","article-title":"Association between visual acuity and residual retinal fluid following intravitreal anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: a systematic review and meta-analysis","volume":"140","author":"Patil","year":"2022","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025000545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025000545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T08:06:57Z","timestamp":1754035617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025000545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2468653025000545"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.02.002","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial Functional and Anatomical Outcomes of High-dose Aflibercept 8 mg in Exudative Neovascular Age-related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00c2\u00a9 2025 Published by Elsevier Inc. on behalf of American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}